- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02262572
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
October 9, 2014 updated by: Boehringer Ingelheim
Relative Bioavailability of Telmisartan and HCTZ p.o. (80 mg Telmisartan/12.5 mg HCTZ) in Two Experimental Formulations (Given t.i.d. for One Day Each) Compared to the Standard Formulation 80 mg Telmisartan/12.5 mg HCTZ (MicardisPlus®), Given t.i.d. for One Day in Healthy Female and Male Subjects. A Three-way Crossover, Open, Randomised Study
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects meeting the following criteria will be eligible for participation in the study:
- Healthy male and female subjects according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests.
- Laboratory values within a clinically defined reference range
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- Age >=18 and Age <=55 years
- Body mass index (BMI) >=18.5 and <=29.9 kg/m2
- Able to communicate well with the investigator and to comply with study requirements
- Good condition of veins
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, heart rate, and electrocardiogram) deviating from normal and of clinical relevance
- Supine blood pressure at screening of systolic ≤ 110 mm Hg and diastolic ≤ 60 mmHg
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of an allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of any drugs, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 10 cigarettes or three cigars or three pipes/day)
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation or loss of more than 400 mL within four weeks prior to administration or during the trial
- Excessive physical activities (within five days prior to administration or during the trial)
- Any laboratory value outside the reference range of clinical relevance
- History of hereditary fructose intolerance
- Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
- Inability to comply with the dietary regimen of study centre
- Inability to comply with the investigator's instructions.
For female subjects:
- Pregnancy
- Positive pregnancy test
- No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
- Inability to maintain this adequate contraception during the whole study period
- Lactation period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telmisartan /HCTZ - compression tablet (DC)
|
|
EXPERIMENTAL: Telmisartan /HCTZ - dry granulation tablet (DG)
|
|
ACTIVE_COMPARATOR: Telmisartan /HCTZ - present commercial formulation
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Cmax (Maximum measured concentration of the analyte in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Amount of HCTZ excreted in urine over 48 hours (%Ae0-48h)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tmax (Time from dosing to the maximum concentration of the analyte in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
t1/2 (Terminal half-life of the analyte in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
CLtot/F (Apparent clearance of the analyte in plasma following extravascular administration)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
MRTtot (Total mean residence time)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Vz/F (Apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Number of subjects with adverse events
Time Frame: up to 32 days
|
up to 32 days
|
|
Number of subjects with clinically significant findings in vital signs
Time Frame: up to 32 days
|
blood pressure, pulse rate
|
up to 32 days
|
Number of subjects with clinically significant findings in 12 lead ECG
Time Frame: up to 32 days
|
up to 32 days
|
|
Investigator's assessment of tolerability on a 4-point scale
Time Frame: up to 32 days
|
up to 32 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2003
Primary Completion (ACTUAL)
August 1, 2003
Study Registration Dates
First Submitted
October 9, 2014
First Submitted That Met QC Criteria
October 9, 2014
First Posted (ESTIMATE)
October 13, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
October 13, 2014
Last Update Submitted That Met QC Criteria
October 9, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Hydrochlorothiazide
- Telmisartan
Other Study ID Numbers
- 502.415
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Telmisartan /HCTZ - compression tablet (DC)
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted